Other genetic epilepsies that can benefit from precision therapy include KCNQ2 (carbamazepine, phenytoin) [90], GLUT1 deficiency, SLC2A1 or CDKL5 (ketogenic diet) [91,92], PCDH19 (clobazam) [93], mutations in KCNQ2, SCN2A, and SCN8A (ion sodium channel blockers), and mTORopathies (mTOR inhibitors) [82,94]. This evidence concerns the gene KCNQ2 and epilepsy.